Deliver Your News to the World

Immunai Selects Mount Sinai, Weill Cornell Medicine, and Harvard’s MGH to Launch Flagship Academic Collaboration


WEBWIRE –

Immunai Inc., a leading AI biotech company specializing in mapping the human immune system, announced the selection of four high-value academic projects to build a larger and clearer picture of how the immune system works across autoimmune disease, solid-tumor immunotherapy, and cell therapy. The selected collaborations include research proposals from the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and Massachusetts General Hospital of Harvard Medical School.

Immunai first announced its Grand Collaboration Initiative for Single-Cell Immune Profiling in August. Upon execution of a Grand Collaboration agreement, the four selected academic researchers will receive free single-cell RNA sequencing and additional multi-omic data to support their research.

The selected collaborations will focus on the following:

  • Autoimmune Kidney Disease (Mount Sinai – Paolo Cravedi, MD, PhD)
    [list]
  • Allowing Immunai to compare immune signatures across conditions with underlying immune dysfunctions.

  • T-Cell Redirection Therapy in Multiple Myeloma (Mount Sinai – Zachary Avigan, MD, MHS, & Samir Parekh, MBBS)
    • A longitudinal dataset capturing immune trajectories, supporting Immunai’s growing efforts in advancing cell therapy and toxicity prediction.

  • Neoadjuvant Immunotherapy in NSCLC (Weill Cornell Medicine – Liron Yoffe, Nasser Altorki & Vivek Mittal)
    • A multi-regimen neoadjuvant cohort that strengthens Immunai’s immuno-oncology data pillar across mechanism-of-action, response prediction, and adverse-event modeling.

  • PD-1 Response and Resistance in Gastric and GEJ Adenocarcinoma (MGH / Harvard Medical School – Ignacio Vazquez-Garcia & Samuel Klempner)
    • A strategically important dataset expanding Immunai’s representation of immunotherapy-treated GI cancers
    [/list]

    “Biotech doesn’t fail from a lack of ideas; it fails from a lack of the right data and a lack of analytical tools to make data-driven decisions,” said Noam Solomon, PhD, CEO and Co-Founder of Immunai. “These new collaborations strengthen AMICA™ where available data is sparse but the clinical needs to provide better solutions across autoimmunity, immuno-oncology, and cell therapy are huge, and they do so at a scale that finally addresses the bottleneck at its source. This is how you build the immune system’s foundation for the next decade of medicine: with diverse, high-resolution, explainable datasets that can generalize across diseases, uncover new targets, and accelerate therapies long before they reach the clinic.”

    To follow along with Immunai’s Grand Collaboration Initiative updates, visit https://www.immunai.com/collaboration/.

    About Immunai
    Immunai is developing an AI model of the immune system, the IDE™ engine, leveraging its large proprietary clinically annotated single-cell multi-omics immunology knowledgebase AMICA™ and advanced artificial intelligence and machine learning, in order to discover and improve the development of novel immune modulating therapeutics. With a team of over 190 experts, Immunai collaborates with leading pharmaceutical companies and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date. Find out more at immunai.com and follow us on LinkedIn and X.


    ( Press Release Image: https://photos.webwire.com/prmedia/42381/349028/349028-1.jpg )


    WebWireID349028





    This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

    News Release Distribution and Press Release Distribution Services Provided by WebWire.